Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM26UKN)

Drug Name
GNF-PF-2224 Drug Info
Synonyms
8-Cyclopentyl-1,3-dipropylxanthine; DPCPX; 102146-07-6; 8-cyclopentyl-1,3-dipropyl-1H-purine-2,6(3H,7H)-dione; 1,3-Dpcpx; 1,3-dipropyl-8-cyclopentylxanthine; PD-116,948; PD-116948; UNII-9PTP4FOI9E; dipropylcyclopentylxanthine; 9PTP4FOI9E; CHEMBL183; MLS000069347; CHEBI:73282; 8-Cyclopentyl-3,7-dihydro-1,3-dipropyl-1H-purin-2,6-dione; 8-cyclopentyl-1,3-dipropyl-7H-purine-2,6-dione; 1,3-DIPROPYL-8-CYCLOPENTYLXANTHINE [DPCPX]; SMR000058434; DPCPX, 1,3-Dipropyl-8-cyclopentylxanthine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
1329
ChEBI ID
CHEBI:73282
CAS Number
CAS 102146-07-6
TTD Drug ID
DM26UKN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Adenosine receptor (ADOR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Theophylline DMRJFN9 Bronchitis CA20 Approved [7]
NIR178 DMPER4A Non-hodgkin lymphoma 2B33.5 Phase 2 [8]
DIADENOSINE TETRAPHOSPHATE DMTJOEL Cardiac arrhythmias BC9Z Phase 2 [9]
M-216765 DMUIGM3 Hypertension BA00-BA04 Terminated [10]
8-sulfophenyl theophylline DMOHB3Z Discovery agent N.A. Investigative [1]
SPT DM94RJW Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Targeting Adenosine A3 receptor (ADORA3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
IB-MECA DM9G5XD Psoriasis vulgaris EA90 Phase 3 [12]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [13]
NITD609 DMQHBSX Malaria 1F40-1F45 Phase 2 [14]
CF102 DMP56WJ Hepatocellular carcinoma 2C12.02 Phase 2 [15]
SCH-442416 DMQ2K1V N. A. N. A. Phase 1 [16]
AST-004 DM5WMG7 Stroke 8B20 Phase 1 [17]
BEMESETRON DMSPJX9 N. A. N. A. Discontinued in Phase 3 [18]
BAY 60-6583 DMTEJV1 Myocardial ischemia BA6Z Preclinical [19]
CF602 DM0ULO2 Inflammation 1A00-CA43.1 Preclinical [15]
CF502 DMQSJ20 Inflammation 1A00-CA43.1 Preclinical [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adenosine A2a receptor (ADORA2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Caffeine DMKBJWP Allergic rhinitis CA08.0 Approved [20]
Istradefylline DM20VSK Parkinson disease 8A00.0 Approved [21]
Regadenoson DM76VHG Radionuclide imaging N.A. Approved [22]
Tozadenant DMATC14 Parkinson disease 8A00.0 Phase 3 [23]
Binodenoson DMVHF8G Hypertension BA00-BA04 Phase 3 [24]
Apadenoson DMD8QTC Coronary artery disease BA80 Phase 3 [25]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [13]
Dexefaroxan DMTY4KN Parkinson disease 8A00.0 Phase 2 [26]
AMP-579 DMJ4GPR Hyperlipidaemia 5C80 Phase 2 [27]
BIIB014 DMH7RJ1 Parkinson disease 8A00.0 Phase 2 [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adenosine A2b receptor (ADORA2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Adenosine DMM2NSK Paroxysmal supraventricular tachycardia BC81.Z Approved [29]
Vidarabine DM0N85H Hepatosplenic T-cell lymphoma Approved [29]
A295 DM55GO2 Aggressive cancer 2A00-2F9Z IND submitted [30]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [13]
YT-146 DM3YVKQ Hypertension BA00-BA04 Phase 2 [31]
AB928 DMDOXMN Metastatic colorectal cancer 2B91 Phase 1/2 [8]
KF-17837 DMQ6DLZ Parkinson disease 8A00.0 Phase 1 [32]
Xanthine DMFBOQ7 Apnea MD11.0 Phase 1 [33]
CVT-6883 DMY84TW Asthma CA23 Phase 1 [34]
PBF-1129 DMOPGXM Non-small-cell lung cancer 2C25.Y Phase 1 [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adenosine A1 receptor (ADORA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Caffeine DMKBJWP Allergic rhinitis CA08.0 Approved [20]
Rolofylline DMSZPR3 Heart failure BD10-BD13 Phase 3 [35]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [13]
AMP-579 DMJ4GPR Hyperlipidaemia 5C80 Phase 2 [27]
SELODENOSON DMQM3IX Cardiac arrhythmias BC9Z Phase 2 [36]
Apaxifylline DMQMV9F Cognitive impairment 6D71 Phase 2 [37]
SLV320 DM867BJ Heart failure BD10-BD13 Phase 2 [38]
DTI-0009 DMV84OK Atrial fibrillation BC81.3 Phase 2 [36]
Capadenoson DMYWO62 Atrial fibrillation BC81.3 Phase 2 [39]
BAY 1067197 DM4JGNH Heart failure BD10-BD13 Phase 2 [40]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Adenosine receptor A2a (ADORA2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [41]
Quercetin DM3NC4M Obesity 5B81 Approved [42]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [43]
Methylprednisolone DM4BDON Acute adrenal insufficiency Approved [44]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [45]
Leflunomide DMR8ONJ Arthritis FA20 Approved [46]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [47]
Adenosine DMM2NSK Paroxysmal supraventricular tachycardia BC81.Z Approved [48]
Azathioprine DMMZSXQ Lupus nephritis 4A40.0Y Approved [44]
Prednisolone DMQ8FR2 Acute adrenal insufficiency Approved [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Adenosine receptor A2b (ADORA2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [41]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [49]
Testosterone DM7HUNW Hot flushes GA30 Approved [50]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [50]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [51]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [47]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [52]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [53]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [54]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [55]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Adenosine receptor A1 (ADORA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [56]
Gefitinib DM15F0X Colon adenocarcinoma Approved [57]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [58]
Testosterone DM7HUNW Hot flushes GA30 Approved [50]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [50]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [47]
Adenosine DMM2NSK Paroxysmal supraventricular tachycardia BC81.Z Approved [48]
Diethylstilbestrol DMN3UXQ Gonorrheal vaginitis GA02 Approved [59]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [60]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [61]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adenosine A1 receptor (ADORA1) TTK25J1 AA1R_HUMAN Inhibitor [1]
Adenosine A2a receptor (ADORA2A) TTM2AOE AA2AR_HUMAN Inhibitor [2]
Adenosine A2b receptor (ADORA2B) TTNE7KG AA2BR_HUMAN Inhibitor [3]
Adenosine A3 receptor (ADORA3) TTJFY5U AA3R_HUMAN Inhibitor [4]
Adenosine receptor (ADOR) TTSLI08 NOUNIPROTAC Antagonist [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Adenosine receptor A1 (ADORA1) OTI7X39E AA1R_HUMAN Protein Interaction/Cellular Processes [5]
Adenosine receptor A2a (ADORA2A) OTVRBZ0I AA2AR_HUMAN Protein Interaction/Cellular Processes [6]
Adenosine receptor A2b (ADORA2B) OTCDYBBP AA2BR_HUMAN Protein Interaction/Cellular Processes [5]

References

1 Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001 Dec;117(6):1594-600.
2 Synthesis and theoretical studies on energetics of novel N- and O- perfluoroalkyl triazole tagged thienopyrimidines--their potential as adenosine r... Eur J Med Chem. 2010 May;45(5):1739-45.
3 Discovery of FK453, a novel non-xanthine adenosine A1 receptor antagonist, Bioorg. Med. Chem. Lett. 6(17):2059-2062 (1996).
4 Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A(1) adenosine receptor ligands. Bioorg Med Chem. 2010 Nov 15;18(22):7890-9.
5 Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2011 Jan 27;54(2):457-71. doi: 10.1021/jm100843z. Epub 2010 Dec 27.
6 Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist. J Med Chem. 2011 Feb 10;54(3):751-64. doi: 10.1021/jm1008659. Epub 2011 Jan 6.
7 Emerging adenosine receptor agonists. Expert Opin Emerg Drugs. 2007 Sep;12(3):479-92.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Negative chronotropic and inotropic effects exerted by diadenosine hexaphosphate (AP6A) via A1-adenosine receptors. Br J Pharmacol. 1996 Nov;119(5):835-44.
10 US patent application no. 2010,0009,934, Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders.
11 Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol. 1995 Mar;27(3):883-92.
12 A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
13 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
14 Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
15 2011 Pipeline of Can-Fite BioPharm.
16 Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
17 Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. Stroke. 2022 Jan;53(1):238-248.
18 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
19 Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
20 Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
21 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
22 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
23 Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
24 Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12.
25 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
26 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
27 Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
28 Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
29 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
30 Clinical pipeline report, company report or official report of Klus Pharma
31 Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10.
32 Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3.
33 Role of adenosine in asthma. Drug Dev Res. 1996;39:333-6.
34 GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012 Dec;343(3):587-95.
35 Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72.
36 Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
37 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779)
38 Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64.
39 A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.
40 Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619.
41 Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action. Arthritis Res Ther. 2012 Jun 8;14(3):R138. doi: 10.1186/ar3871.
42 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
43 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
44 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
45 Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
46 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
47 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
48 New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile. Purinergic Signal. 2007 Sep;3(4):339-46. doi: 10.1007/s11302-007-9068-9. Epub 2007 Sep 19.
49 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
50 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
51 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
52 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
53 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
54 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
55 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
56 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
57 Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep. 2006 Jun;15(6):1453-60.
58 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
59 Analysis of gene expression induced by diethylstilbestrol (DES) in human primitive Mullerian duct cells using microarray. Cancer Lett. 2005 Apr 8;220(2):197-210.
60 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
61 Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.